Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Lung cancer

The Medical Clinics of North America

|November 1, 1977

Summary

This summary is machine-generated.

Localized lung cancer patients benefit from curative resection or radiotherapy. For nonlocalized tumors, treatments offer limited survival benefits, though palliative care and chemotherapy show promise for specific types like small cell lung cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment of tuberculosis.

The American review of respiratory disease·1983

Same author

Shortened chemotherapy for pulmonary tuberculosis.

The New England journal of medicine·1982

Same author

Accelerated growth of lung cancer in association with rifampicin administration for tuberculosis.

Lancet (London, England)·1981

Same author

[Unusual cause of hemoptysis: pulmonary hypoplasia].

Revista clinica espanola·1981

Same author

Transfer factor treatment in a patient with progressive tuberculosis.

Clinical immunology and immunopathology·1977

Same author

The destroyed tuberculous lung.

Scandinavian journal of respiratory diseases·1974

Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026

Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026

Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026

Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026

Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026

Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026

See all related articles

Area of Science:

Oncology
Pulmonology
Cancer Research

Background:

Lung cancer treatment efficacy varies significantly based on disease stage.
Surgical resection is a primary curative option for localized lung cancer.
Non-surgical curative options and palliative treatments are crucial for unresectable or advanced disease.

Purpose of the Study:

To delineate the effectiveness of various lung cancer treatment modalities.
To identify patient populations that benefit from specific therapies like surgery, radiotherapy, and chemotherapy.
To evaluate the palliative and curative potential of different lung cancer treatments.

Main Methods:

Review of existing clinical data and treatment guidelines for lung cancer.
Analysis of outcomes for localized versus nonlocalized lung cancer patients.

Related Experiment Videos

Assessment of adjuvant therapy, radiotherapy, chemotherapy, and immunotherapy effects.

Main Results:

Curative resection benefits only localized lung cancer patients.
Radiotherapy is recommended for medically inoperable localized tumors and offers palliative benefits in 50-75% of symptomatic patients.
Adjuvant therapies do not improve surgical outcomes, except for Pancoast tumors; chemotherapy is effective for small cell lung cancer.

Conclusions:

Treatment selection for lung cancer must be stage-dependent for optimal outcomes.
Radiotherapy plays a key role in both curative settings (for inoperable cases) and palliative care.
Chemotherapy, particularly for small cell lung cancer, offers significant survival benefits and tumor regression, while immunotherapy remains investigational.